Evaluation of a novel nimodipine delivery system in conscious rats that allows sustained release for 24 h.
Methodologies that allow prolonged drug administration in animal models, while minimizing surgery and anesthesia, are an important contribution towards studies in awake conditions. Commercially available drug delivery systems like pellets can be customized for the evaluation of experimental therapies with minimal or no discomfort to animals. Our objective was to evaluate pharmacokinetic and physiologic parameters after subcutaneous implantation of rapid 24 h release nimodipine pellets in rats for their potential use as a delivery system for stroke therapeutics. A day prior to the study Sprague-Dawley rats were anesthetized (halothane, N2O, O2) for femoral vessel cannulation and later returned to their cages. On the day of the study the rats were briefly anesthetized (identical regimen as before), and assigned to two groups: nimodipine (NP) and placebo (PL). NP rats received either 0.5 (n = 4), 1 (n = 3), 2 (n = 2), 4 (n = 2), or 15 (n = 5) mg pellets (Innovative Research of America Inc., Sarasota, FL, USA) and PL, rats (n = 5) received placebo pellets. Nimodipine plasma levels were measured at 1, 3, and 6 h. In addition, the 15 mg NP group was followed at 18 and 24 h. Immediately following decapitation the brain was removed for later determination of nimodipine tissue concentration. The NP 15 mg group showed a significant decline of 10% in MABP from base line to 24 h post implantation (p < 0.001). All NP animals achieved at least 83% of their highest plasma concentration at 1 h and 94% at 3 h. A high degree of correspondence (r2 = 0.95, y = 0.36 + 0.28x, n = 16) between the plasma and brain concentrations of nimodipine was present. Although a significant drop in MABP was observed the drop was no greater than 10% in 24 h. Plasma nimodipine levels for the 15 mg animals were within the cerebrovascular effective range. This is the first report to show that 24 h release nimodipine pellets subcutaneously implanted in rats are a reliable delivery system that allows rapid rise and constant nimodipine plasma levels. Therefore, 24 h release pellets are a suitable alternative to other delivery systems like osmotic pumps.
Perez-Trepichio
A D
AD
Cleveland Clinic Foundation, Dept. Biomedical Engineering, OH 44195, USA.
Jones
S C
SC
D000818:Animals; D001921:Brain / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods*; D009553:Nimodipine / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley
D009553:Nimodipine